miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44

Abstract

Introduction: Metastasis and drug resistance contribute substantially to the poor prognosis of colorectal cancer (CRC) patients. However, the epigenetic regulatory mechanisms by which CRC develops metastatic and drug-resistant characteristics remain unclear. This study aimed to investigate the role of miR-302a in the metastasis and molecular-targeted drug resistance of CRC and elucidate the underlying molecular mechanisms.Methods: miR-302a expression in CRC cell lines and patient tissue microarrays was analyzed by qPCR and fluorescence in situ hybridization. The roles of miR-302a in metastasis and cetuximab (CTX) resistance were evaluated both in vitro and in vivo. Bioinformatic prediction algorithms and luciferase reporter assays were performed to identify the miR-302a binding regions in the NFIB and CD44 3'-UTRs. A chromatin immunoprecipitation assay was performed to examine NFIB occupancy in the ITGA6 promoter region. Immunoblotting was performed to identify the EGFR-mediated pathways altered by miR-302a.Results: miR-302a expression was frequently reduced in CRC cells and tissues, especially in CTX-resistant cells and patient-derived xenografts. The decreased miR-302a levels correlated with poor overall CRC patient survival. miR-302a overexpression inhibited metastasis and restored CTX responsiveness in CRC cells, whereas miR-302a silencing exerted the opposite effects. NFIB and CD44 were identified as novel targets of miR-302a. miR-302a inhibited the metastasis-promoting effect of NFIB that physiologically activates ITGA6 transcription. miR-302a restored CTX responsiveness by suppressing CD44-induced cancer stem cell-like properties and EGFR-mediated MAPK and AKT signaling. These results are consistent with clinical observations indicating that miR-302a expression is inversely correlated with the expression of its targets in CRC specimens.Conclusions: Our findings show that miR-302a acts as a multifaceted regulator of CRC metastasis and CTX resistance by targeting NFIB and CD44, respectively. Our study implicates miR-302a as a candidate prognostic predictor and a therapeutic agent in CRC.

Hsa_circ_0026416 promotes proliferation and migration in colorectal cancer via miR-346/NFIB axis

“…NFIB appeared in all four databases and has been reported as a target gene of miR-346 in glioma [32]. Moreover, NFIB was identified as an oncogene in CRC [31,43]. THPA database and qRT-PCR experiment both demonstrated that NFIB was upregulated in CRC.…”

Mcl-1 inhibition overcomes intrinsic and acquired Regorafenib resistance in Colorectal Cancer

“…However, most CRCs are either inherently insensitive to therapeutic treatment or acquire resistance upon relapse 3 . There is a critical need for developing novel and more effective CRC therapies, especially for those with intrinsic or acquired resistance to existing treatments 30 .…”

miRNA Clusters with Down-Regulated Expression in Human Colorectal Cancer and Their Regulation

“…The inhibitory effects of miR-302a-3p are mediated via the MAPK and PI3K/Akt signalling pathways [ 160 ]. The tumour suppressor role of miR-302a-3p is also executed by targeting nuclear factor IB ( NFIB ) and the induction of cetuximab chemosensitivity, which is caused by suppressing cell-surface expression of the glycoprotein CD44 [ 161 ]. miR-302a-3p also induces 5FU sensitivity and viability inhibition via the inhibition of IGF1R [ 162 ].…”